3,319 Shares in IQVIA Holdings Inc. $IQV Purchased by Caprock Group LLC

Caprock Group LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,319 shares of the medical research company’s stock, valued at approximately $633,000.

Other large investors have also recently modified their holdings of the company. Versant Capital Management Inc grew its position in shares of IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after purchasing an additional 53 shares in the last quarter. Private Trust Co. NA grew its holdings in IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after buying an additional 67 shares in the last quarter. CVA Family Office LLC increased its position in shares of IQVIA by 11.6% during the third quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after buying an additional 68 shares during the period. UMB Bank n.a. boosted its position in shares of IQVIA by 11.0% in the third quarter. UMB Bank n.a. now owns 749 shares of the medical research company’s stock valued at $142,000 after acquiring an additional 74 shares during the period. Finally, E Fund Management Co. Ltd. boosted its position in shares of IQVIA by 3.7% in the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 74 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Evercore reiterated an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a research note on Thursday, February 5th. TD Cowen increased their price objective on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. BMO Capital Markets set a $250.00 target price on IQVIA in a research report on Friday, February 6th. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Finally, Truist Financial lifted their price target on IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $238.20.

IQVIA Stock Down 1.3%

Shares of NYSE:IQV opened at $166.70 on Tuesday. The stock’s 50-day moving average is $221.98 and its 200 day moving average is $209.06. The company has a market cap of $28.39 billion, a PE ratio of 21.21, a P/E/G ratio of 1.61 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.